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Summary 
The  rapamycin-sensitive  signaling  pathway  is required 
to  transduce  specific  mitogenic  signals  to  the  cell  cy 
cle  machinery  responsible  for  Gl  progression.  Genetic 
studies  in  yeast  identified  two  related  genes  on  this 
pathway,  TOR7  and  TOR2,  thought  to  encode  novel 
phosphatidylinositol  kinases.  We  now  show  that  an 
intact  kinase  domain  Is  required  for  the  Gl  cell  cycle 
functions  of  both  proteins,  for  the  ability  of  a  mutation 
in  a  neighboring  FKBP12-rapamycin-binding  domain 
of  the  TORl  protein  to  inhibit  the  growth  of  yeast  cells 
when  overexpressed,  and  for  the  essential  function  of 
the  TOR2  protein.  The  Gl  function  of  both  TOR  pro- 
teins  is sensitive  to  rapamycin,  but  the  essential  func- 
tion  of  TOR2  is  not.  Thus,  FKBPlIL-rapamycin  does 
not  appear  to  inhibit  the  kinase  activity  of  TOR  proteins 
in  a  general  way;  instead,  it  may  interfere  selectively 
with  TOR  protein  binding  to  or  phosphorylation  of  Gl 
effecters. 
Introduction 
The  bacterially  deriyed  immunosuppressants  FK508  and 
rapamycin  have  proved  to  be  useful  tools  for  dissecting 
the  signaling  pathways  that  result  in  resting  T cells  making 
a  commitment  to  divide  (Schreiber,  1992).  This  process 
requires  two  distinct  signals  delivered  in  tandem.  Signals 
emanating  from  the  T cell  receptor  (TCR)  render  the  cell 
competent  for  cell  division  by establishing  a  second,  auto- 
crine  signaling  pathway  involving  interleukin-2  (IL-2)  and 
the  IL-2  receptor  (IL-2R).  Signals  from  the  IL-2R  commit 
the  cell  to  a  program  of  cell  division  by  communicating 
with  components  of  the  cell  cycle  machinery  necessary 
for  DNA  replication.  Although  both  FK508  and  rapamycin 
inhibit  the  ability  of T cells  to  divide  by  binding  to  the  same 
immunophilin  receptor  (FKBP12),  the  resulting  complexes 
target  different  signaling  pathways.  FKBP12-FK508  inhib- 
its the  TCR  signaling  pathway  by  binding  to  and  inhibiting 
the  phosphatase  activity  of  calcineurin,  one  of  the  com- 
ponents  of  the  TCR  pathway;  a  second  immunosuppres- 
sant-immunophilin  complex,  cyclosporin-cyclophilin,  also 
inhibitscalcineurin  (Liu  et al.,  1991).  In contrast,  FKBPIP- 
rapamycin  inhibits  the  IL-2R  signaling  pathway  by binding 
to  a  289  kDa  kinase  named  FRAP  in  humans  and  RAFT 
in  rats  (Brown  et  al.,  1994;  Sabatini  et  al.,  1994;  Chiu  et 
al.,  1994).  In  effect,  the  immunosuppressants  have  two 
protein-binding  surfaces  that  mediate  the  heterodimeriza- 
tion  of  target  proteins  (immunophilins  and  the  signaling 
proteins  calcineurin  and  FRAP)  and  can,  thus,  be  consid- 
ered  as analogous  to  proteins  such  as Grb2,  which  hetero- 
dimerize  their  targets. 
Although  the  rapamycin-sensitive  target  was  first  exam- 
ined  in  T cells,  it is used  by  many  eukaryotic  cells  to  com- 
municate  changes  in  cell  growth  circumstances  to  the  cell 
cycle  machinery  necessary  for  DNA  replication.  For  exam- 
ple,  low  concentrations  of  rapamycin  induce  Gl  cell  cycle 
arrest  in  yeast.  Genetic  studies  in  the  yeast  Saccharo- 
myces  cerevisiae  identified  two  related  genes,  TO/?7  and 
TOR2, containing  apparent  open  reading  frames  encoding 
2470  amino  acids  and  2474  amino  acids,  respectively 
(Heitman  et al.,  1991;  Cafferkey  et al.,  1993;  Kunz  et  al., 
1993;  Helliwell  et al.,  1994).  The  highest  degree  of similar- 
ity,  with  over  80%  amino  acid  identity,  resides  in  their 
C-termini,  which  are  related  to  the  catalytic  domains  of 
phosphatidylinositol  (PI)  kinases.  This  C-terminal  kinase 
domain  is interchangeable  between  TOR7  and  TOR2,  sug- 
gesting  they  have  similar  functions  (Helliwell  et al.,  1994). 
That  the  proteins  themselves  have  distinct  functions  is 
evident  from  studies  of  the  for7  null  mutant,  which  has 
only  a  partial  growth  defect  under  normal  growth  condi- 
tions,  and  the  for2  null,  which  has  a  lethal  phenotype  with 
cells  arrested  randomly  in  the  cell  cycle.  Like  treatment 
with  rapamycin,  the  for7  tor2  double  disruption  results  in 
Gl  arrest  (Kunz  et  al.,  1993;  Helliwell  et  al.,  1994).  When 
the  conserved  serine  residues,  Ser-1972  in  7OR7  and  Ser- 
1975  in  TOR2,  are  changed  to  isoleucine  or arginine,  either 
gene  confers  dominant  rapamycin  resistance. 
The  C-terminal  kinase  domains  in  FRAP  and  TOR  are 
more  than  80%  identical.  The  substrate(s)  of  these  do- 
mains  has  not  yet  been  identified,  despite  their  apparent 
similarity  to  the  PI3-kinase  (Pl3K)  and  PICkinases  (Pl4K). 
The  two  cloned  Pl3Ks,  the  ~110  Pl3K  in  mammals  and 
Vps34  in  yeast,  also  have  protein  kinase  activity  (Dhand 
et  al.,  1994;  Stack  and  Emr,  1994).  Although  the  conse- 
quences  of  the  two  kinase  activities  are  currently  un- 
known,  roles  have  been  established  for  these  proteins  in 
several  signaling  pathways,  including  mitogenic  pathways 
(for  reviews  see  Carpenter  and  Cantley,  1990;  Divecha 
and  Irvine,  1995). 
In  this  study,  we  show  that  TORl  binds  directly  to 
FKBPl2-rapamycin  and  that  a  small  region  surrounding 
Ser-1972,  the  FKBPl2-rapamycin-binding  (FRB)  domain, 
is sufficient  for  mediating  this  interaction.  Substitution  of 
Ser-1972  with  residues  larger  than  serine  abolish  this  inter- 
action  both  in  vivo  and  in  vitro  and  confer  dominant  rapa- 
mycin  resistance,  although  substitution  with  alanine  does 
not.  Genetic  analyses  indicate  that  the  kinase  domains  in 
both  TOR  proteins  are  required  for  their  rapamycin- 
sensitive  Gl  functions.  Point  mutations  that  inactivate Cdl 
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known  PI  and  protein  kinases  (kinasedead  mutations) 
were  found  to  abolish  the  ability  of  the  TOR  mutants  at 
Ser-1972  (TOM)  and  Ser-1975  (TOR2)  to  allow  growth  in 
the  presence  of  rapamycin  and  to  abolish  the  ability  of 
one  of these,  TORl  (Ser-1972+le),  to  produce  a  unique, 
dominant  cell  growth  inhibitory  phenotype  when  overpro- 
duced.  Furthermore,  overproduction  of  a  TOR  kinase- 
dead  mutant  causes  Gl  cell  cycle  arrest.  These  results 
establish  that  the  kinase  domains  of  TOR  proteins  are 
essential  for  Gl  cell  cycle  progression  in  yeast.  We  also 
show  that  a  function  of TOR2  that  is required  for  cell  viabil- 
ity,  the  essential  function,  is  dependent  on  a  functional 
TOR  kinasedomain.  This  essential  function  is nonetheless 
resistant  to  the  actions  of  rapamycin,  in  contrast  with  its 
Gl  function.  The  results  suggest  that  FKBPl2-rapamycin 
may  interfere  with  the  binding  or  phosphorylation  of  Gl 
effecters  only,  rather  than  inhibit  the  kinase  activity  of TOR 
proteins  in  a  general  way.  These  studies  indicate  that  the 
TOR/FRAP  proteins  define  a  novel  family  of  kinases  and 
that  the  kinase  domains  of  these  proteins  are  essential 
for  their  cellular  functions. 
Results 
TOM  Binds  to  Yeast  FKBPlP-Rapamycin 
Both  In  Vivo  and  In  Vitro 
Two  mammalian  homologs  of  TOR  proteins,  FRAP  and 
RAFT,  have  recently  been  purified  using  FKBPl2-rapa- 
mycin  affinity  matrices  (Brown  et  al.,  1994;  Sabatini  et 
al.,  1994).  We  have  used  a  similar  strategy  to  examine 
whether  TORl  and  TOR2  proteins  bind  directly  to  the 
yeast  FKBPlP  (yFKBPlP)-rapamycin  (using  glutathione 
S-transferase  [GSTj-yFKBP12  fusion  protein  complexed 
to  rapamycin;  yGFK-rapamycin)  complex.  A  single,  ap- 
parently  low  abundance  polypeptide  of  M,  220,999  from 
crude  yeast  lysates  was  specifically  retained  on  a  yGFK- 
rapamycin  column,  but  not  to yGFK-FK506  or yGFK  alone 
(Figure  1A).  The  gel  mobility  of the  yeast  protein  is similar 
to  that  of  human  FRAP  (Brown  et  al.,  1994)  suggesting 
the  proteins  are  related.  Indeed,  the  220  kDa  protein  was 
recognized  specifically  by  an  anti-TORl  immune  serum, 
but  not  the  preimmune  serum  on  a  Western  blot  (Figure 
1B).  We  generated  yeast  mutants  carrying  the  chromo- 
somal  mutations  Ser-1972+Arg  in  TO/W  or  Ser-1975wArg 
in  TOR2  by homologous  recombination.  The  Ser-1972  mu- 
tation  in  TORl  abolished  the  binding  of  this  protein  to 
yGFK-rapamycin  in two  independent  mutant  strains,  while 
no  effect  was  observed  with  the  TOR2  mutant  strains  (Fig- 
ure  1C).  Thus,  the  229  kDa  protein  purified  by  yGFK- 
rapamycin  appears  to  be  TORl  , and  mutation  at Ser-1972 
prevents  its  binding  to  yFKBPlP-rapamycin.  Since  a 
TOR2  fragment  has  been  shown  to  bind  to  FKBP12-rapa- 
mycin  in a yeast  two-hybrid  assay  (Stan  et al.,  1994)  TOR2 
most  likely  also  binds;  our  inability  to  detect  such  binding 
in  the  TORl  mutant  strains  may  be  due  to  its  low  level  of 
expression. 
Deletional  analyses  using  an  in  vitro  transcription-trans- 
lation  system  (rabbit  reticulocyte  lysates)  indicate  that 
TORl  with  a  C-terminal  truncation  up  to  amino  acid  2157 
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Figure  1.  TORI  Binds  Directly  to  FKBPlP-Rapamycin  Complex 
(A  and  B) S.  cerevisiae  yeast  lysates  were  applied  to  a Mono0  column. 
After  extensive  washing,  samples  were  eiuted  with  1  M  NaCI.  The 
eluants  were  incubated  with  0.7  pM  yGFK  alone,  yGFK-FK599,  or 
yGFK-rapamycin  and  were  allowed  to bind  to a gtutathione  S-Sepharose 
(GTS)  column.  The  GTS-bound  material  was  washed,  eluted  into  SDS 
gel  sample  buffer,  separated  by7.5%  (A,  top,  and  S)or  2o%  (A,  bottom) 
SDS-polyacrylamide  gel  electrphoresis,  and  analyzed  by  silver  stain- 
ing  (A),  by  immunoblot  with  anti-TORI  immune  serum  (B,  top)  or  with 
preimmune  serum  (6.  bottom)  as  a  control. 
(C)  TORl  (Ser-1972+Arg)  does  not  bind  to  an  FKBPlP-rapamycin 
complex.  The  following  haploid  yeast  strains  were  used  for  the  yGFK- 
rapamycin  binding  assay:  wild  type  (MATa,  TO/V,  TOR2),  two  indepen- 
dent  clones  (TOR7-7  and  TOM-2)  of  the  mutant  (MATa,  TOP7  [Ser- 
1972*Arg],  TOR2),  and  two  independent  clones  (TOR2-1  and  TOff2- 
12)  of  the  mutant  (MATa,  TOR7,  TOP2  [Ser-1975+Arg]).  The  purifica- 
tion  procedure  is  the  same  as  Figure  IA.  The  final  yGFK-  or  yGFK- 
rapamycin-bound  materials  were  analyzed  by  silver  staining. 
is  able  to  bind  to  yGFK-rapamycin.  A  further  removal  of 
21  amino  acids  abolishes  this  binding  (Figure  2A).  We 
found  a 45  kDa  fragment  of TORl  (TORl-45,  amino  acids 
1775-2157)  containing  Ser-1972  was  sufficient  to  bind  to 
yGFK-rapamycin.  Two  naturally  selected  dominant  rapa- 
mycin-resistant  mutations  at  Ser.1  972,  arginine  and  iso- 
leucine,  disrupt  yGFK-rapamycin  interaction  wfth  TOR145 
completely.  Similarly,  glutamic  acid,  a  residue  potentially 
analogous  to  phosphoserine,  also  abolishes  the  ability  of 
TOR1-45  to  bind  yGFK-rapamycin.  In  contrast,  alanine, 
a  potential  mimic  of  unphosphorylated  serine,  does  not 
affect  yGFK-rapamycin  binding  (Figure  28). Function  of  TOR  Kinase  Domains 
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Figure  2.  Mapping  FRB  Domain  in  TORl 
(A)  A  series  of  “S-labeled  TORI  deletional  mutants  was  generated  in 
vitro,  incubated  with  0.7  PM  yGFK  or  yGFK-rapamycin,  and  purified 
onto  GTS  columns.  The  GTS-bound  materials  were  eluted  into  SDS 
protein  gel  sample  buffer,  separated  on  SDS  protein  gels,  and  ana- 
lyzed  by  X-ray  autoradiography.  Bars  indicate  different  truncated 
TORI  s.  Plus  indicates  TORl  fragments  that  bind  to  yGFK-rapamycin; 
minus  indicates  TORl  domains  that  do  not  bind  to  yGFK-rapamycin. 
(B)  Assay  for  the  effects  of  substitutions  at  Ser-1972  on  the  binding 
of  TORl  to  FKBPlP-rapamycin.  The  abilii  of  %-labeled  wild-type 
TOR1-45,  or  Ser-1972+Ala,  Ser-1972+Glu,  Ser-1972+lle,  and  Ser- 
1972+Arg  mutant  TOR1-45  (FRB  domain)  to  bind  yGFK  or  yGFK- 
rapamycin  wasassayed  similarly  to  (A).  Total  indicates  total  %-labeled 
TOR145  FRB  used.  S,  wild-type  Ser-1972;  A,  Ala-i  972;  E,  Glu-1972; 
I,  118-1972;  R,  Arg-1972. 
(C)  Overexpression  of  FRB  domain  of  TORl  allows  yeast  to  resist 
rapamycin.  S.  cerevisiae  EGY43  (Gyuris  et  al.,  1993)  expressing  the 
Cells  expressing  the  Ser-1972+Arg,  Ser-1972-116,  and 
the  Ser-1972+Glu  mutants,  which  fail  to  bind  to  FKBP12- 
rapamycin,  were  able  to  resist  rapamycin  (Table  1). In  con- 
trast,  the  Ser-1972eAla  mutant,  which  retains  the  ability 
to  bind  FKBPlP-rapamycin,  was  unable  to  confer  resis- 
tance  to  rapamycin.  When  the  FRB  domain-containing 
TOR145  is overproduced,  yeast  cells  were  able  to  grow 
normally  in  100  nM  rapamycin,  a  concentration  at  which 
the  growth  of  normal  yeast  cells  is  completely  inhibited 
(Figure  2C).  In  contrast,  cells  expressing  TOR145  (Ser- 
1972-Arg),  a mutant  that  does  not  bind  yGFK-rapamycin 
in vitro,  are  sensitive  to  rapamycin  (Figure  2C).  Thus,  these 
in  vivo  assays  for  the  interaction  between  FKBP12-rapa- 
mycin  and  TORl  confirm  the  results  obtained  in  the  in 
vitro  biochemical  experiments  and  suggest  that  TORl 
binding  to  FKBP12-rapamycin  occurs  in  vivo. 
The  Kinase  Domains  in  TORl  and  TOR2  Are 
Essential  for  Their  Gl  Functions 
Because  of their  sequence  similarity  with  other  PI kinases, 
proteins  of the  TORlFRAP  family  were  anticipated  to  have 
PI kinase  activities.  Thus  far,  we  have  tested  in vitro  kinase 
activities  of recombinant  TORl  proteins  produced  in  yeast 
and  E.  coli  and  FRAP  proteins  expressed  in  E.  coli  and 
mammalian  and  Sf9  cells  toward  PI,  PI phosphate  deriva- 
tives,  and  several  other  potential  lipid  substrates.  We  have 
been  unable  to  demonstrate  any  such  activity  with  TORl 
or  FRAP  proteins.  We  also  carried  out  HPLC  analyses  of 
total  cellular  PI phosphate  products,  using  in vivo  PH]inosi- 
tol  labeling,  following  rapamycin  treatment  or  overexpres- 
sion  of TORl  proteins.  Nosignificant  alterations  in  PI phos- 
phate  products  were  observed  (X.-F.  Z.,  P.  A.  Beal,  and 
S.  L.  S.,  unpublished  data).  Since  Pl3K  and  Vps34  were 
previously  shown  to  exhibit  protein  kinase  activity,  we  also 
examined  whether  TORl  and  FRAP  have  intrinsic  protein 
kinase  activity.  To  facilitate  this  analysis,  we  introduced 
two  kinase  inactivation  substitutions,  Arg-2276+Pro  and 
Asp-2294*Glu,  into  the  wild-type  TOR7  and  Ser-1972 
TO/?7  dominant  rapamycin-resistant  mutants.  The  analo- 
gous  kinase-dead  mutations  were  shown  previously  to 
abolish  the  activities  of Pl3K  and  Vps34,  respectively  (Schu 
et al.,  1993;  Dhand  et  al.,  1994),  and  we  have  shown  that 
similar  mutations  in  FRAP  abolish  a  serine-autophos- 
phorylation  activity  in  wild-type  FRAP  and  its  Ser-2035 
(corresponding  to  Ser-1972  in  TORl)  mutant  expressed 
in  mammalian  (E.  J.  Brown,  P.  A.  Beal,  J.  Chen,  T.-B. 
Shin,  and  S.  L. S.,  unpublished  data)  and  Sf9  cells  (P.  A. 
Beal,  C.  Keith,  and  S.  L. S.,  unpublished  data).  However, 
we  have  not  been  able  to  obtain  conclusive  biochemical 
evidence  for  a  protein  kinase  activity  in  wild-type  TORl 
expressed  in  yeast  cells.  It is  possible  that  the  autophos- 
TOR145  FRBdomain  was  assayed  for  rapamycin  sensitivity.  TOR1-45 
(FRB)  expression  is  under  the  control  of  the  GAL1  promoter  (GAL,  2 
PM.  MA).  Yeast  cells  were  streaked  onto  uracildropout  plates  con- 
taining  glucose  or  galactose  supplemented  with  or  without  100  nM 
rapamycin,  and  incubated  at  30%  for  3  days.  Rapamycin  resistance 
was  scored  by  the  ability  of  the  cells  to  form  colonies.  A,  control;  8, 
wild-type  TOR1-45  (FRB);  C,  Ser-1972+Arg  mutant  TOR145  (FRB). Cdl 
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Table  1.  Effect  of  Mutations  on  TORl 
Mutation 
Ser-1972  (wt) 
Ser-1972  Arg-2276-Pro 
Ser-1972  Asp2294-Glu 
Ser-1972-Ala 
Ser-1972+Arg 
Ser-1972+ArglArg-2276+Pro 
Ser-1972+Arg/Asp2294+Glu 
Ser-1972-rGlu 
Ser-1972+Glu/Arg-2276+Pro 
Ser-1972+Glu/Asp-2294+Glu 
Ser-1972~lie 
Ser-1972+lle/Arg-2276+Pro 
Ser-1972+lle/Asp-2294+Glu 
ND,  not  determined. 
GFK-Rap  Binding 
Yes 
ND 
ND 
Yes 
No 
No 
No 
No 
No 
No 
No 
No 
No 
Rapamycin  Resistance 
No 
No 
No 
No 
Yes 
No 
No 
Yes 
No 
No 
Yes 
No 
No 
Complementation  of  Temperature 
Sensitivity  of  Atorl 
Yes 
ND 
ND 
Yes 
ND 
ND 
ND 
ND 
ND 
ND 
Yes 
ND 
ND 
phorylation  site  on  TORl  does  not  exist  or  that  the  condi- 
tions  for  yeast  cell  lysis  are  too  harsh  to  preserve  this 
activity.  By taking  a genetic  approach,  we  have  succeeded 
in  revealing  the  importance  of  the  kinase  domains  in  TOR 
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Figure  3.  Kinase  Domains  Are  Essential  for  Rapamycin-Sensitive  Gl 
Functions  of  TORI  and  TOR2 
(A)  S. cerevisiae  BJ6469  expressing  wild-type  or  mutant  TORl  proteins 
under  the  control  of  the  gafactose-inducible  promoter  (GAL,  2  pM, 
TRP)  were  assayed  for  their  sensitivity  to  100  nM  rapamycin  as  in 
Figure  X.  A,  control;  8,  wild-type  TORl;  C.  TORl  (Ber-1972+lle);  D, 
TORl  (Ser-1972~lle/Arg2276+Pro);  E,  TORI  (Ser-1972Me/Asp- 
2294~Giu). 
(B)  BJ6469  expressing  TORZ  or  TOR2-TOW  wild-type  and  mutant 
genes  (ARSUXN,  LEU)  were  asseyed  for  their  sensttttity  to  166  nM 
rapamyctn.  A,  TOR2;  8,  TCR2-TORI;  C,  TOf?2-TORl  (Ser-197Wlte); 
D,  TOR2-TORI  (Ser-1972+lle/Arg2276+Pro);  E,  TORP-TORI  (Ser- 
1972-+e/Asp-2294+Glu). 
proteins,  and  we  find  that  the  cellular  effect  of  the  muta- 
tions  discussed  above  correlate  precisely  with  their  effect 
on  the  protein  kinase  activity  observed  with  FRAP.  Both 
TORl  kinasedead  mutations  abolish  the  ability  of the  Ser- 
1972+lle  mutant  to confer  dominant  rapamycin  resistance 
when  the  double  mutants  (Ser-1972+lle/Arg-22764Pro 
and  Ser-1972+lle/Asp2294+Glu)  were  expressed  at low 
levels  in  glucose  medium  (Figure  3A).  Similar  effects  were 
also  seen  with  the  Ser-1972+Glu  and  the  Ser-1972+Arg 
double  mutants  (Table  1).  It was  previously  established 
that  the  C-terminus  of  both  7OR7  and  TOR2  are  function- 
atly  interchangeable  (Hetfffll  et al.,  1994).  We  engineered 
chimeric  TOR  proteins  comprising  the  N-terminus  of 
TOR2  and  C-terminus  of  TORl.  The  wild-type  chimeric 
TORP-TORl  protein  (CEN4,  LEU)  complements  the  for2 
null  strain,  showing  that  it is an  active  and  functional  pro- 
tein  and  confirming  the  earlier  report(Helliwell  et al.,  1994; 
see  Figure  6).  However,  the  two  kinasedead  mutations 
abolish  the  ability  of the  serine  TOR2  mutant  to  resist  the 
actions  of  rapamycin  (Figure  36). 
Kinasedead  mutants  of  protein  kinases  often  exhibit  a 
dominant  negative  effect  on  growth  by  interacting  in  a 
nonproductive  way  with  effector  proteins  normally  associ- 
ating  with  the  wild-type  kinase.  We  found  that  the  Arg- 
2276ePro  and  the  Asp-2294-01~  TORI  mutants,  when 
overproduced  following  gala&se  induction,  inhibii  growth 
of yeast  cells  cultured  on  solid  (but  not  liquid)  medium  as 
shown  in  Figure  4; ffow  cytometric  analysis  revealed  these 
cells  undergo  Gl  cell  cycle  arrest  (data  not  shown).  This 
observatii  indicates  that  the  kinasedead  TORl  proteins 
exhibit  a  dominant  negative  effect  on  TORl  function. 
Since  the  tori  null  mutation  alone  does  not  cause  Gl  ar- 
rest,  the  dominant  negative  TORI  mutants  must  interfere 
with  the  Gl  functions  of  both  TOR  proteins. 
An  Intact  Kinase  Domain  Is  Also  Required  for  the 
Ser-1972-Ne  Mutatlon  in  TORl  to  lnhlbit  Cell 
Growth  Oomirmtly 
When  tested  for  rapamycin  sensitivity  under  galactose  in- 
duction,  the  TORl  (Ser-1972+lle)  mutant  prevented  growth 
of  yeast  cells  in  a  rapamycin-independent  manner,  even Function  of  TOR  Kinase  Domains 
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Figure  4.  Overexpression  of  TOM  Kinase-Dead  Mutants  Cause  Gl 
Cell  Cycle  Arrest 
S.  cerevisiae  SJ5459  expressing  wild-type  or  mutant  TORl  proteins 
under  the  control  of  the  GAL7  promoter  (GAL,  2 uM,  TRP)  were  assayed 
for  their  ability  to  grow  on  glucose  or  galactose  media.  A, control;  B, the 
wild-type  TOW;  C,  TORl  (Arg-2276-tPro);  D,  TORI  (Asp2294*Glu). 
though  its  low  level  of  expression  in  the  presence  of  glu- 
cose  is  sufficient  to  resist  rapamycin.  in  liquid  culture, 
yeast  cells  overexpressing  the  wild-type  TORl  protein  or 
its  Ser-1972eAla  mutant  have  a  normal  growth  rate  that 
is comparable  to that  of yeast  cells  carrying  a control  vector 
(Figure  5).  In  contrast,  the  growth  of  yeast  ceils  overex- 
pressing  the  TOFU  (Ser-1972*lle)  protein  was  signifi- 
cantly  diminished.  This  dominant  growth-arresting  effect  is 
dependent  upon  the  existance  of an  intact  kinase  domain. 
When  the  kinase-inactivating  mutations  Arg-2276+Pro  or 
Asp2294+Glu  were  introduced  into  TORl  (Ser-1972+le), 
the  dominant  growth  inhibitory  effect  of the  Ser-1972~lie 
mutation  was  lost  (Figure  5). This  difference  in  growth  inhi- 
bition  is not due  to  a higher  level  of TOR  protein  expression 
by the  TORl  (Ser-1972+lle)-expressing  cells,  as judged 
by  Western  blots  (data  not  shown).  This  growth-arresting 
phenotype  of the  TOR7  (Ser-1972-118)  allele  is clearly  dif- 
ferent  from  the  dominant  negative  effects  seen  with  ki- 
nase-dead  TORl  mutants.  The  TORI  (Ser-1972+lle)  mu- 
tant  allele  appears  to  preserve  all  the  normal  function  of 
wild-type  TOR,  as  evidenced  by  its ability  to  resist  the  ac- 
tions  of  rapamycin  and  by  its  ability  to  complement  the 
tor2  null  as a  chimeric  protein  with  a  TOR2  N-terminus.  In 
addition,  the  dominant  negative  effect  of the  kinase-dead 
TORI  mutants  is seen  only  on  solid  medium.  In  contrast, 
overexpression  of  TORl  (Ser-1972-,lle)  causes  cell 
growth  arrest  in  both  liquid  (Figure  5)  and  solid  (data  not 
shown)  cultures.  The  effects  of  overexpression  of  TORl 
(Ser-1972*lle)  mutant  on  cell  cycle  progression  and  check- 
points  are  currently  under  investigation. 
TOFU  Has  an  Essential  Function  That  Is  Not 
Inhibitable  by  FKBP12-Rapamycin 
To  investigate  whether  the  function  of  TOR2  is  sensitive 
to  the  actions  of  rapamycin,  we  engineered  a  tori  null 
strain  by  inserting  a  LEU2  marker  into  the  Bamlil  site  of 
TOR7  gene  in the  kinase  domain  (Figure  6A).  This  insertion 
has  been  shown  previously  to  knock  out  the  function  of 
the  TOR7  gene  (Kunz  et  al.,  1993;  Helliwell  et  al.,  1994). 
The  Ator7  strain  was  found  to  undergo  Gl  cell  cycle  arrest 
when  treated  with  rapamycin,  indicating  that  the  TOR2 
protein  is a target  of the  actions  of  rapamycin  in  vivo  (Fig- 
ure  6A).  Despite  the  fact  that  a tor2  disruption  in  a wild-type 
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Figure  5.  Dominant  Growth  Arrest  by  Overexpression  of  TORl  (Ser- 
1972elle)  Is  Dependent  on  an  Intact  Kinase  Domain 
Yeast cells  expressing  wild-type  or  mutant  TORl  proteins  under  the 
control  of  galactose-inducible  promoter  (GAL,  2  PM,  TRP)  were  as- 
sayed  for  their  ability  to  grow  under  conditions  of  galactose  induction. 
The  overnight  yeast  cultures  in  glucose  were  diluted  into  sucrose  me- 
dia  at  OD,  =  0.25  and  were  incubated  for  4  hr  at  30%.  The  cells 
were  harvested  bycentrifugation,  resuspended  intogalactose  medium 
at  ODem  =  0.25,  and  incubated  at  30%.  Aliquots  of  cultures  were 
withdrawn  at  different  times  for  OD  measurement  at  666  nM. 
TOR7  background  is lethal,  the  TO/?7  (Ser-1972-Arg)  mu- 
tant  allele  allows  yeast  to  grow  in  the  presence  of  rapa- 
mycin.  These  observations  suggest  that  if rapamycin  in- 
hibits  all functions  of TOR2,  then  the  TORl  (Ser-1972-+Arg) 
mutant,  but not  the  wild-type  TORI,  causes  a gain  of TORl 
function  that  should  complement  the  for2  null  lethal  pheno- 
type.  We  tested  this  by  disrupting  the  TOR2  gene  either 
in  a  wild-type  TOR7  or  a  TO/37  (Ser-1972*Arg)  mutant 
background  (Figure  6B).  First,  diploid  heterozygous  TO/W 
for2  mutants  in  either  a  wild-type  TOR7i7OR7  or  mutant 
homozygous  TOR7SRITORl  SR background  were  gener- 
ated  by  inserting  a  LEU2  marker  into  the  BamHI  site  in 
the  kinase  domain  previously  shown  to  inactivate  the 
TOR2  gene  (Helliwell  et  al.,  1994).  Tetrad  analyses 
showed  that  in  both  genetic  backgrounds,  only  two  or  less 
viable  spores  (versus  four)  were  obtained  (Figure  68). 
None  of  the  viable  spores  were  found  to  cosegregate  with 
the  LEUP  marker,  indicating  that  in  either  genetic  back- 
ground,  the  for2  disruption  is  lethal.  This  result  demon- 
strates  that  the  TORl  (Ser-1972+Arg)  mutation  does  not 
complement  the  lossof  theTOR2essentialfunction.  Given 
the  dominant  rapamycin-resistant  phenotype  of this  TORl 
mutation  and  the  sensitivity  of  TOR2  to  rapamycin,  we 
conclude  that  the  essential  function  of  TOR2,  in  contrast 
with  its  Gl  function,  is  not  inhibited  by  FKBP12-rapa- 
mycin.  This  is consistent  with  the  observation  that  treating 
the  tori  null  strain  described  above  with  rapamycin  re- 
sulted  in  Gl  cell  cycle  arrest,  which  is in  contrast  with  the 
random  cell  cycle  arrest  phenotype  observed  with  the  tor2 
null  strain. TORI/TORI  TOR2/twZA 
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Figure  6.  TOR2  Has  an  Essential  Function  That  Is  Not  Sensitive  to 
Rapamycin 
TORI  or  TOP2  gene  was  disrupted  by  insertion  of  a  marker  gene  into 
the  conserved  SamHI  site.  The  small  arrows  indicate  PCR  primers  for 
analyzing  the  disruption  results.  The  small  bar  shows  the  TORI  or 
TOR2  sequence  used  for  making  the  disruption  constructs. 
(A)  Yeast  cells  lacking  TOM  are  still  sensitive  to  rapamycin.  Haploid 
wild-type  or  tor7  null  yeast  cells  were  assayed  for  sensitivity  to  196 
nM  rapamycin.  A,  wild-type  yeast  (MATa,  TORI,  TOR2);  6,  mutant 
yeast  (MATa.  TOR7  [Ser-1972+Arg],  TO&);  C  and  D,  two  clones  of 
tori  disrupted  strains  (MATa,  torl::LEU,  7DR2). 
(8)  TORI  (Ser-1972+Arg)  does  not  complement  lethality  associated 
with  TOFt2  disruption.  Dipbkl  yeast  heterozygous  for  TOR2  disruption 
in  a wild-type  TORI  background  (MATa/a,  TOR7/TOR1,  TOFt2Ror2d:: 
LEU)  or  a  Ser-i97&Arg  mutant  TOFU  background  (MATala,  TORI 
[Ser-1972+Arg]/TORI  [Ser-1972+Arg],  TORMor2::LEU)  were  al- 
lowed  to  sporulate.  Tetrads  were  dissected,  and  viable  spores  were 
grown  into  colonies.  In  either  genetic  background,  tetrad  analyses 
always  show  a  2:2  or  a  16  segregation  of  viable  versus  nonviable 
spores. 
(C)  The  kinase  domain  is  required  for  the  essential  function  of  TOf?2. 
Diptotd  yeast  cells  carrytng  a  heterozygous  TOR2  disruption  (TORY 
tor2dMG-URA-H/SO)  and  plasmid-born  wild-type  and  mutant  TOR2 
or  TOR2-TOR7  fusion  genes  (L/X/2,  ARSAXN)  under  the  endogenous 
TOR2  promoter  were  sporulated.  Dissected  spores  were  grown  on 
YPD  plates,  from  which  replica  Et/-  or  URAdmpout  plates  were  made. 
Viable  spores  were  counted  with  URA  marker  from  a  total  of  viable 
Since  the  specificity  of  the  essential  function  of  TOFt2 
is determined  by  its N-terminus  (Helliwell  et  al.,  1994),  we 
asked  whether  this  essential  function  requires  a functional 
kinase  domain.  We  established  diploid  yeast  strains  with 
a  heterozygous  insertion  of a  URA  marker  into  the  BamHl 
site  of  the  TOR2  gene  (TOR2/?or2).  Piasmids  expressing 
extrachromosomal  (CEN4,  LEU2)  TOR2,  TOR2-TOM, 
TOR2-TORl(SI),  TORP-TORl(DE),  TOR2-TORl(SI/DE) 
were  then  introduced  into  the  heterozygotes.  After  sporu- 
lation,  we  examined  how  the  LEU2  and  URA  markers  asso- 
ciate  in  the  viable  spores.  Of  the  -  40  viable  spores  show- 
ing  LEU2  prototrophy  for  each  strain,  half  were  found  to 
have  the  URA  marker  for  cells  expressing  TOR2,  TOR2- 
TORl,  and  TOR2-TORl(SI),  but  none  were  found  to  have 
the  URA  marker  with  cells  expressing  the  kinase-dead 
TOR  proteins  (Figure  6C).  Thus,  the  essential  function  of 
TOR2  requires  a  functional  kinase  domain. 
Discussion 
TOR7  (or DRR 7) and  TORP(or  DRR2)  genes  were  originally 
isolated  as  mutations  at  a  conserved  residue,  Ser-1972 
in  TORl  or  Ser-1975  in  TOR2,  that  confer  a  dominant 
rapamycin-resistant  phenotype  in  yeast  (Cafferkey  et  al., 
1993;  Helliwell  et  al.,  1994).  Our  results  demonstrate  that 
TOR  proteins  are  direct  targets  of  FKBPl2-rapamycin. 
TORl  and  TOR2  (this  study)  and  their  mammalian  homo- 
logs  FRAP  (Brown  et  al.,  1994)  and  RAFT  (Sabatini  et 
al.,  1994)  bind  directly  to the  FKBPl  P-rapamycin  complex 
during  in  vitro  purification  or  in  a two-hybrid  yeast  screen- 
ing  (Chiu  et al.,  1994).  Isorapamycin,  a  rapamycin  deriva- 
tive  that  binds  FKBP12  with  high  affinity  but  is a poor  inhibi- 
tor  of  cell  cycle  progression,  binds  less  efficiently  to  both 
FRAP  (Brown  et  al.,  1994)  and  TORl  (X.-F.  Z.  and  S.  L. 
S.,  unpublished  data).  Mutational  analyses  indicate  that 
the  conserved  residues,  Ser-1972  in  TORl  and  Ser-1975 
in  TOR2,  are  essential  for  interaction  with  FKBP12-rapa- 
mycin  in  both  our  in  vivo  and  in  vitro  binding  studies.  The 
steric  requirements  for  this  residue  are  highly  stringent. 
Serine  and  alanine  are  permissive  for  the  binding  of 
FKBPl2-rapamycin,  whereas  larger  residues  abolish  this 
interaction.  These  binding  results  correlate  well  with  the 
ability  of  mutant  TOR  proteins  to  resist  the  inhibitory  ac- 
tions  of  rapamycin.  Mutations  that  disrupt  binding  of 
FKBP12-rapamycin  to  TOR  proteins  confer  rapamycin  re- 
sistance  in  an  in  vivo  assay.  In contrast,  the  Ser-1972+Ala 
mutant,  which  binds  FKBP12-rapamycin,  is as  sensitive 
to  rapamycin  as  wild-type  TORl  . On  the  other  hand,  the 
gene  encoding  the  Ser-1972+Ala  mutant  appears  to  have 
normal  TOR7  function,  as  shown  by  its  ability  to  comple- 
ment  the  temperature  sensitivity  of  a  tori  mutant  strain 
(Table  1). A  small  FRB  domain  of TORl  surrounding  Ser- 
1972  is suff icient  for  binding  to  the  complex.  When  overex- 
spores  carrying  LEU2.  Rescue  of  the  lethality  caused  by  TOR2  disrup- 
tion  was  determined  by  analyzing  the  cosegregation  of  the  two 
markers. Function  of  TOR  Kinase  Domains 
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pressed,  this  domain  also  allows  cells  to  resist  the  actions 
of  rapamycin,  indicating  that  such  binding  occurs  in  vivo. 
In contrast,  when  the  domain  containing  the  Ser-1972+Arg 
mutation  that  disrupts  binding  to  FKBPlP-rapamycin  in 
vitro  is overexpressed,  it does  not  produce  the  rapamycin- 
resistant  phenotype.  Together,  these  results  establish  that 
binding  to  the  FRB  domain  is essential  for  the  Gl  inhibitory 
function  of  FKBPlP-rapamycin  and  that  the  conserved 
serine  residue  is critical  for  this  interaction. 
PI kinases  and  their  phospholipidderived  products  have 
been  shown  to  be  important  in  a  variety  of  cellular  pro- 
cesses,  including  mitogenic  signaling  pathways  (for  re- 
views  see  Carpenter  and  Cantley,  1990;  Divecha  and  Ir- 
vine,  1995).  The  kinase  domain  among  TOR-related 
proteins  from  yeast  to  humans  is highly  conserved,  show- 
ing  over  60%  identity  between  TORl  and  human  FRAP 
in  this  region.  However,  a  phylogenetic  analysis  reveals 
that  FRAP,  TO/W,  TOR2,  MECl/ESRl,  and  e2787(TELI) 
appear  to  constitute  a  third  family  of  “lipid”  kinases  that 
have  clearly  diverged  from  the  Pl3K  and  Pl4K  families, 
which  themselves  are  phylogenetically  distinct  from  each 
other  (C. Keith  and  S. L. S., unpublished  data).  Consistent 
with  this  analysis,  we  have  not  been  able  to  demonstrate 
TOR-  or  FRAP-catalyzed  phosphorylation  of  a  variety  of 
potential  lipid  substrates,  including  PI and  PI phosphates, 
and  lipid  extracts  from  cells.  In  addition,  we  have  not  de- 
tected  any  change  in  the  concentration  of cellular  PI phos- 
phates  following  rapamycin  treatment  of yeast  cells  labeled 
in  vivo  with  [3H]inositol,  or  following  the  overexpression 
of  the  TORl  protein.  Although  we  have  not  been  able  to 
obtain  conclusive  biochemical  evidence  for  a  protein  ki- 
nase  activity  in  wild-type  TORl  expressed  in  yeast,  possi- 
bly  due  to  the  harsh  conditions  required  for  the  lysis  of 
yeast  cells,  we  have  been  able  to  demonstrate  a  serine 
autophosphorylation  kinase  activity  in  wild-type  FRAP  and 
Ser-2035  mutants  of FRAP  expressed  in mammalian  (E.  J. 
Brown,  P. A. Beal,  J. Chen,  T.-B.  Shin,  and  S. L. S., unpu  b- 
lished  data)  and  Sf9  cells  (P. A. Beal,  C. Keith,  and  S.  L.  S., 
unpublished  data).  It is therefore  likely  that  TOR  proteins 
and  their  analogous  Ser-1972/Ser-1975  mutants  also  have 
protein  kinase  activity. 
In  this  study,  w&  have  taken  a  chemical/genetic  ap- 
proach  to study  the  role  of the  kinase  domains  in  mediating 
TOR  functions.  Rapamycin,  which  causes  Gl  cell  cycle 
arrest  in  yeast,  has  been  used  as  a  chemical  equivalent 
of  a  loss-of-function  conditional  allele  of TOR  proteins:  its 
inclusion  in  functional  experiments  results  in  the  loss-of- 
function  of endogenousTOR  proteins.  Since  the  Ser-19721 
Ser-1975  TOR  mutants  described  above  do  not  bind 
FKBPl  P-rapamycin,  they  have  been  used  in  the  presence 
of  rapamycin  to  assess  the  functional  role  of  TOR  kinase 
domains.  We  find  that  kinasedead  mutations  analogous 
to  those  that  inactivate  the  lipid  and  protein  kinase  activity 
of  PI  kinases,  and  the  protein  kinase  activity  of  FRAP, 
abolish  the  ability  of the  dominant  rapamycin-resistant  mu- 
tations  in  both  TORl  and  TOR2  to  resist  the  actions  of 
rapamycin.  These  experiments  with  double  mutants  es- 
tablish  that  an  intact  kinase  domain  is  essential  for  the 
Gl  functions  of both  TOR  proteins.  In  addition,  when  over- 
expressed,  the  kinase-dead  single  mutants  of TORI  men- 
tioned  above  show  a  dominant  negative  phenotype,  re- 
sulting  in  Gl  cell  cycle  arrest  of  yeast  growing  on  a  solid 
medium.  Since  TORl  and  TOR2  appear  to  have  redun- 
dant  Gl  functions,  the  kinasedead  TORl  protein  may 
bind  to  the  Gl  effecters  common  to  TORl  and  TOR2, 
inhibiting  the  action  of  both  wild-type  proteins. 
In experiments  that  do  not  rely  upon  the  actions  of rapa- 
mycin,  we  found  that  overproduced  TORl  (Ser-1972+lle), 
but  not  the  wild-type  or TORl  (Ser-1972-+Ala)  mutant  pro- 
teins,  dominantly  inhibits  cell  proliferation  by a mechanism 
that  is also  dependent  upon  its  kinase  domain  (Figure  5). 
Although  we  have  not fully  characterized  the  resulting  phe- 
notype,  preliminary  experiments  suggest  that  overexpres- 
sion  of this  Ser-1972  mutant  may  interfere  with  the  function 
of  a  cell  cycle  checkpoint  (X.-F.  2.  and  S.  L.  S.,  unpub- 
lished  data).  The  TORl  (Ser-1972+lle)  mutant  appears 
to  preserve  the  normal  functions  of the  wild-type  protein, 
as  it  allows  cells  to  resist  rapamycin  dominantly,  it  sup- 
presses  the  temperature  sensitivity  of a for7  mutant  (Table 
l),  and  its  C-terminal  domain  (including  the  kinase  and 
mutant  FRB  domains)  provides  the  essential  TOR2  func- 
tion  when  fused  to  the  N-terminal  domain  of TOR2.  Thus, 
growth  inhibition  is not  due  to  a  dominant  negative  effect. 
The  growth  inhibitory  phenotype  of  the  TORl  (Ser- 
1972-lle)  mutant  may  be  due  to the  constitutive  modifica- 
tion  of aTOR  effector,  possibly  due  to  an  activating  influ- 
ence  of  the  isoleucine  group  on  the  kinase  of  TORl. 
Changes  in  the  conserved  serine  residue  may  provide  a 
conformational  basis  for  kinase  activation.  Ser-1972  and 
its flanking  sequences  are  found  in  the  kinase  domain  of 
FRAP  and  TOR  proteins,  but  not  in  the  kinase  domains 
of the  known  PI kinases.  Thissequence  may  be  analogous 
to  ones  found  in  the  regulatory  domains  of  the  serinel 
threonine  kinases  PKG  and  PKC  (these  domains  are  also 
immediately  N-terminal  to  the  kinase  domains)  and  the 
homologous  regulatory  subunits  RI and  RII of  PKA.  Stud- 
ies  of  these  protein  kinases  indicate  that  the  putatively 
analogous  sequences  act  as  inhibitory  pseudosubstrates, 
interacting  directly  with  the  kinase  active  site.  A  striking 
similarity  in  the  kinases  of  the  FRAP/TOR  family  and  the 
CAMP-dependent  protein  kinase  PKA  is  that  in  both  in- 
stances  the  key  serine  residue  in  the  regulatory  domain 
can  be  mutated  to  alanine  without  removing  the  binding 
properties  of  the  domains,  while  mutation  to  larger  resi- 
dues  results  in  potent  inhibition  of  binding  (Buechler  and 
Taylor,  1991).  Ourobservationssuggest  that Ser-1972  and 
its surrounding  FRB  domain  may  be  behaving  in a way  that 
is analogous  to the  RII subunit  of  PKA  and  the  N-terminal 
regulatory  subunit  of  PKG. 
The  TOR  poteins  are  functionally  and  structurally  re- 
lated,  yet  they  also  have  distinguishing  features.  The  C-ter- 
minal  kinase  domains  of  the  TOR  proteins  can  be  inter- 
changed  without  loss  of  function  (Helliwell  et  al.,  1994), 
and  certain  mutations  at the  conserved  serine  in their  FRB 
domains  in  either  protein  allow  yeast  to  resist  the  actions 
of  rapamycin  dominantly.  Double  disruption  of  TON  and 
TOR2  results  in  Gl  cell  cycle  arrest,  and  as  shown  above, 
in  both  cases  their  Gl  function  requires  an  active  kinase Cdl 
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domain.  In  addition,  the  dominant  negative  TORl  kinase- 
dead  mutant  arrests  the  cell  cycle  in  Gl  , as  does  rapa- 
mycin.  These  results  suggest  that  the  kinase  domains  of 
both  proteins  share  a  common  Gl  function.  But,  although 
the  loss  of  TOR7  only  slightly  affects  yeast  cell  growth, 
the  loss  of  TOR2  is lethal  and  results  in  random  cell  cycle 
arrest  (Kunz  et al.,  1993).  The  dominant  nature  of the  FRB 
domain  mutations  in TORl  ,  which  allow  yeast  to proliferate 
even  though  both  endogenous  TORsare  inhibited  by rapa- 
mycin,  suggests  that  the  mutations  may  lead  to  a  gain  of 
TORl  function  that  complements  the  functions  of  TOR2. 
Although  rapamycin  inhibits  at least  the  Gl  function  of the 
TOR2  protein  as  evidenced  by  the  rapamycin  sensitivity 
of  a  tori  null  strain  (see  above),  and  TOR2  is an  essential 
gene,  rapamycin-treated  yeast  harboring  the  TORl  (Ser- 
1972+Arg)  mutation  do  not  show  the  tor2  null  lethal  phe- 
notype,  suggesting  specifically  that  the  TOR7  mutation 
may  suppress  this  phenotype.  An  alternative  explanation 
is that  rapamycin  might  inhibit  only  a  subset  of the  func- 
tions  of  TOR2  and  that  in  the  presence  of  rapamycin  its 
essential  function  is still  intact.  This  is  indeed  suggested 
by  the  finding  that  the  rapamycin-treated  tofl  null  strain 
is  observed  to  arrest  specifically  in  Gl,  suggesting  that 
rapamycin  might  target  only  the  Gl  function  of the  TOR2 
protein  and  not  its essential  function.  To  test  this,  we  stud- 
ied  whether  a  dominant  rapamycin-resistant  TOR7  mutant 
could  suppress  the  lethality  of a  for2  null  mutation.  Tetrad 
analyses  with  diploid  yeast  containing  a  heterozygous 
TOR2  allele  (TOR2/.4for2)  in  either  a  wild-type  TOR7/TOR7 
or  homozygous  mutant  TOR7  (Ser-1972+Arg)/TOR7  (Ser- 
1972+Arg)  background  revealed  that  in  either  genetic 
background,  the  tor2  null  is  lethal.  Thus,  although  rapa- 
mycin  inhibits  the  Gl  function  of the  TOR2  protein,  it does 
not  inhibit  a  second,  essential  function  of  the  protein.  We 
tested  whether  this  TOR2  essential  function  requires  an 
intact  kinase  domain  by complementing  the  tor2  null  with 
plasmid-born  wild-type  or  kinasedead  mutant  TOR2- 
TO/?7  fusion  genes.  Only  those  genes  with  an  intact  kinase 
domain  were  able  to  rescue  the  lethality  associated  with 
the  TOR2  disruption.  Thus,  this  essential  TOR2  function 
also  requires  a functional  kinase  domain.  Since  both  rapa- 
mycin-sensitive  and  -insensitive  functions  of TOR2  require 
a  functional  kinase  domain,  FKBPI  2-rapamycin  does  not 
appear  to  inhibit  directly  the  kinase  activity  of  TOR  pro- 
teins. 
A  model  that  explains  the  dual  functions  of  the  kinase 
domain  in  TOR2  is shown  in  Figure  7.  Distinct  effecters 
for  the  Gl  and  essential  functions  of TOR2  may  associate 
with  separate  domains  of  TOR2.  We  propose  that  the  Gl 
effector  binds  to  the  C-terminal  conserved  domain,  while 
the  effector  for  the  essential  function  binds  to  the  unique 
N-terminal  domain.  Presumably,  the  Gl  effector  is  able 
to  bind  to  the  same  region  of  the  TORl  protein.  The  ef- 
fectors  may  be  involved  in  localization,  where  a  thus  far 
hidden  TOR2  lipid  kinase  activity  could  be  envisioned, 
may  be  modulated  by  a  phospholipid  and/or  adenine  nu- 
cleotide  complex  involving  the  kinase  domain,  in  analogy 
to  guanine  nucleotide  complexes  of  guanine  nucleotide- 
binding  proteins,  or  most  simply  may  be  a  substrate  for  a 
Figure  7.  A  Model  of  TOR  Proteins  and  Their  Functions 
The  TOR2  protein  has  at  least  two  functions  that  require  an  intact 
kinase  domain.  Only  its  Gi  function  is  sensitive  to  rapamycin.  We 
propose  that  FKSPIP-rapamycin  interferes  with  the  association  or 
phosphorylation  of  a  Gi  effector  of  both  TORl  and  TOR2,  but  not 
an  effector  of  the  essential  function  of  TOR2. 
protein  kinase  activity  in TOR2.  Since  FKBPl2-rapamycin 
does  not  appear  to  inhibit  the  catalytic  activity  of the  kinase 
of  TOR2  in  a  general  way,  it may  instead  selectively  pre- 
vent  the  Gl  effector  from  binding  to  or  being  phosphory- 
lated  by  TOR2. 
TOR  proteins  and  their  mammalian  FRAP  homologs  me- 
diate  mitogenic  signaling  pathways  distinct  from  the  Ras- 
MAPK  and,  in  mammalian  cells,  Jak-Stat  pathways.  The 
present  work  reveals  that  TORl  and  TOR2  are  complex, 
multidomainal  proteins  that  use  their  kinase  activities  to 
effect  multiple  cell  cycle  functions,  and  it provides  insights 
into  the  mechanism  by which  FKBPlP-rapamycin  inhibits 
Gl  cell  cycle  progression. 
Experlmental  Procedures 
Yeast Strains  and  Genetlc  Methods 
Standard  procedures  for  culturing  and  mating  strains,  diploid  isolation, 
sporulation,  and  tetrad  analyses were  used  (Guthrie  and  Fink,  1991). 
S.  cerevisiae  strains  used  in  this  study  are  listed  in Table  2.  The  two 
yeast  haploid  strains  carrying  the  Ser-1972+Arg  mutation  in  TORf 
and  Ser-1975+Arg  mutation  in  TOR2,  respectively,  were  derived  from 
YFKO07  (Briruela  et  al.,  1991)  by  integrating  an  approximately  900 
bp  PCR  products  containing  either  Ser-1972eArg  (AGC  to  AGG)  in 
7OR7  or  Ser-1975+Arg  (AGT  to  AGG)  in  TOR2.  These  were  confirmed 
by  sequencing.  An  HO  gene  in pOLl6  was  used  to  construct  wild-type 
or  homozygous  mutant  diploid  YFKOO7  yeast  strains  from  correspond- 
ing  haploid  yeast  strains. 
Away  for  TOR  I Memctkms  wlth  FKBP12-Ftapamycln 
To  purify  yeast  FRB  proteins  from  yeast  S.  cerevisiae,  approximately 
0.5  lb  of  baker’s  yeast  was  lysed  with  glass  beads  in  TSSN+  (50  mM 
Tris-HCI,  150  mM  NaCI,  5  mM  NaF,  1 mM  N&VO,,  1 @ml  leupeptin, 
1  @ml  aprotinin,  1  &ml  trypsin  inhibitor,  1  mM  PMSF.  1 mM  DlT, 
1%  NP40  (pH  7.5)).  Lysates  were  cleared  twice  by  centrifugation  for 
30  min  at  25,000  x  g at  4OC.  The  pH  of  the  supernatant  was  adjusted 
to  7.5  with  1  N  NaOH.  The  lysate  was  then  loaded  onto  a  Mono  Q 
column.  After  extensive  washing  with  TBSN+,  the  bound  material was 
eluted  with  1  M  NaCl  TSSN+  and  the  eluant  was  equally  divided  into 
three  fractions,  each  of  which  was  incubated  with  0.7  PM  yGFK  alone, 
yGFK-FK505,  or  yGFK-rapamycin  for  15  min  at 4X  and  loaded  onto 
glutathione  SSepharose  cdumn  (GTS,  Soehringer).  After  washed 
with  1 M  NaCl  TBSN+  extensively,  the  GTS-bound  material  was  eluted 
into  2 x  protein  gel  sample  buffer,  separated  on  SDS-polyacrylamide Function  of  TOR  Kinase  Domains 
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Table  2.  S.  cerevisiae  Strains 
Strain  Genotype  Source 
BJ5459  MATa  ura3-52  trpl  lys2-801  leu2Al  his3A20  can1  pep4::his3  prblAl.GR  B.  Jones 
EdY46  MATa  ura3  his3  Wp3  LEXAop-leu2  E.  Golemis 
NKY260  MATafa  ura3/ura3  leu2Neu2  N.  Kleckner 
YFKO07  MATa  ads101  lewd1  lys2-801 tfpA1  ura3-52  S.  Parent 
YFKlSR  MATa  ad+101  /e&Al  IysZ-801  @-Al  ura3-52  TORl  (Ser-1972+Arg)  This  study 
YFK2SR  MATa  ade-107  /e&Al  /ysZ-801  @-Al  ura3-52  TOR2  (Ser-1975+Arg)  This  study 
dYFKOO7  MATa/a  ads101  /e&Al  1~~2-801  trp-Al  ura3-52  TORlfTORl  This  study 
dYFK1  SR  MATa/a  ade701  lewd1  lys2-801 trpdl  ura352  TORl  (Ser-1972-Arg)/TORl  (Ser-1972eArg)  This  study 
YFKtorlA  MATa  ade-101  leu-Al  Iys2-801  trp-Al  ura3-52  torlA::LEU2  This  study 
dYFKtor2A  MATaIa  ada-  lewd1  lys2-801 &p-Al  ura3-52  TORVTORl  tor2A/TORZ  This  study 
dYFKlSRtor2A  MATa/a  a&l01  lewd1  /ysZ-801 trpA7  ura3-52  TORl  (Ser-1972-ArgyTORI  (Ser-1972+Arg)  torZA/TORZ  This  study 
YMWl  MATa,  ade2-1  ade-3(A22)  his3-11,15  /eu2-3,112  trpl-1  can-100  wra3-1  M.  Walhberg 
gel,  and  analyzed  by  silver  staining  and  by  immunoblotting  with  anti- 
TORI  antiserum  or  preimmune  serum.  For  analyses  of  mutant  TOR 
proteins,  2 litersof  YFKO07,  YFKl  SR,  and  YFK2SR.  respectively,  were 
grown  to  saturation  in  YPD.  Cells  were  harvested,  and  the  binding 
assays  were  performed  as  described  above. 
To  map  regions  of  TORI  necessary  for  binding  to  FKBP12-rapa- 
mycin,  TORl  cDNA  corresponding  to  residues  1100-2470  was  sub- 
cloned  into  pBluescript  SK-EE  vector,  in which  TORl  is  fused  in frame 
to  a  Glu-Glu  epitope.  The  resulting  plasmid  was  digested  with  the 
following  restriction  enzymes  (the  number  indicates  the  last  amino 
acid  residue  of  the  translation  products):  Smal  (2470).  Aatll  (2441), 
Aflll(2303),  Bglll(2257),  EcoRV  (2157),  Hindlll(2036),  BamHl(1660), 
and  was  used  directly  for  in  vitro  transcription/translation  in  rabbit 
reticulocyte  lysates  to  prepare  “S-labeled  TORl  deletion  mutant  pro- 
teins.  The%-labeled  TORl  proteinswere  incubated  with  0.7  pM  yGFK 
alone,  yGFK-FK506,  or  yGFK-rapamycin  for  15  min  at  4%.  diluted 
50  times  into  ice-cold  TN  buffer  (50  mM  Tris,  1 M  NaCl  [pH  8.0]),  and 
loaded  onto  a  GTS  column.  After  washing  with  ice-cold  TN  buffer 
extensively,  the  GTS-bound  materials  were  eluted  into  2 x  protein  gel 
sample  buffer,  separated  on  SDS-polyacrylamide  gel,  and  analyzed 
by  autoradiography.  TOR1-45  (residues  1766-2159)  was  generated 
with  the  following  pair  of  primers  by  PCR  with  PFU  DNA  polymerase 
(Stratagene)  from  plasmids  containing  wild-type  or  TORl  mutants  at 
Ser-1972  as  templates:  5’-CG  GGA  TCC  GCC  ATG  GTT  CAG  GAA 
GAG  ACT-3’  and  5°C  CGA  ATT  CTA  GAT  ATC  CAA  ATG  TCT  CTT 
GAA-3’.  The  amplified  DNAs  were  subcloned  into  pETSa.  This  plasmid 
was  then  linearized  with  EcoRl  and  used  for  in  vitro  transcription. 
Isolation  of  TORI  and  TOR2  Genes  from  S.  -revMae 
A  genomic  DNA  library  was  constructed  in  pRS315  from  a  spontane- 
ous  dominant  rapamycin-resistant  yeast  mutant  and  was  introduced 
into  a wild-type,  rapamycin-sensitive  yeast  strain.  A  plasmid  that  con- 
ferred  resistance  to  100  nM  rapamycin  was  recovered  and  found  to 
be  identical  to  the  TOR7  gene,  except  with  a mutation  converting  Ser- 
1972  to  isoleucine.  The  corresponding  wild-type  TOR7  gene  was  iso- 
lated  by  gap  repair  of  Bgllltut  plasmid  in wild-type  yeast.  The  TOR2 
genes  were  isolated  similarly.  To  introduce  a  convenient  restriction 
site  for  subcloning,  the  wild-type  and  mutant  TORl  plasmids  were 
replaced  at  the  5’  end  with  a  Sacl  site  followed  by  the  second  amino 
acid  of  TORl  using  PCR  with  the  following  pair  of  primers:  5%AG 
CTC  TTG  AAC  CGC  ATG  AGG  AGC  AGA  TIT  GG-3’  and  5”ACG  GGG 
CCC  AAG  GGA  ACT  GCC-3’.  The  PCR  product  was  digested  with 
Sacl-Spel  and  was  used  to  replace  the  same  restriction  fragment  of 
the  original  genomic  clones. 
Immunological  Techniques 
To  generate  TORl-specific  antiserum,  the  GST-TORl  (1223-2361) 
was  expressed  as  inclusion  bodies,  purified  conveniently  by  washing 
the  cell  pellets  after  lysis,  and  injected  into  rabbits.  After  boosting  twice 
with  antigens,  the  antisera  tested  positive  for  TORl  on  a Western  blot. 
Western  blot  analyses  were  carried  out  as  decribed  previously  (Harlow 
and  Lane,  1966).  Antigens  were  detected  using  the  ECL  method  (Amer- 
sham).  The  anti-TORl  serum  was  used  at  a  dilution  of  1 :lOOO.  The 
anti-flu  hemaglutinin  monoclonal  antibody,  MAb  12CA5,  was  used  at 
1:300  dilution.  For  immunoprecipitation,  cell  lysates  were  incubated 
with  MAb  120%  antibody  at  a  dilution  of  1300  for  1  hr  at  4%.  The 
immunocomplexes  were  captured  with  protein  G-conjugated  Sepha- 
rose  by  incubating  for  another  hour  at  4%,  washed  three  times  with 
TBSN+,  and  three  times  with  TBS  plus  1 mM  DlT.  The  final  immuno- 
precipitates  were  either  directly  used  for  in  vitro  kinase  assays,  or 
were  eluted  into  SDS  protein  sample  buffer  for  Western  blot  analyses. 
TORT  Expresslon  Plasmld  Constructs  and 
In  Vltro  Mutagenesis 
To  create  a  galactose-inducible  yeast  expression  vector,  the  G6PD 
promoter  region  of  pG-1  (2  NM,  TRP)  (Schena  et  al.,  1991)was  inserted 
into  the  BamHl  site  with  the  following  oligo  sequence  encoding  an  5’ 
HA  epitope:  5’-T  ACC  ATG  GGA  TAC  CCA  TAC  GAT  GlT  CCA  GAT 
TAC  GCT  TGG  TAC  CAT  GGA  GCT  CGA  GTC  GAC  GGA  C-3’  and 
5°C  GTC  GAC  TCG  AGC  TCC  ATG  GTA  CCA  AGC  GTA  ATC  TGG 
AAC  ATC  GTA  TGG  GTA  TCC  CAT  GGT  AGA  TC-3’.  The  Smal-Sacl 
fragment  containing  the  G6PD  promoter  of  the  HA  epitope-modified 
pG1  was  replaced  with  a Xhol  (blunted)-Sacl  fragment  containing  the 
GAL70  promoter  from  YCPIFI  5.  The  full-length  TORl  was  then  cloned 
into  this  expression  vector  with  a  HA  tag  on  its  immediate  5’  end. 
To  introduce  mutations  at  Ser-1972,  the  Sacll-Kpnl  fragment  of 
TORl  was  subcloned  into  pBluescript  SK(+)  (Stratagene)  (pBluescript 
TORlSK).  In  vitro  phagemid  mutagenesis  was  carried  out  with  the 
following  primers:  Ser-1972-Ala,  5’-ATGTTCAACGAGCG- 
GGCCGCATClTCCAGTCCTTCA-3’;  Ser-1972+Glu,  5’ATGTTCAA-  - 
CGAAAAATTGGCGlTCCGCATCTTCCAGTCClTC-3’;  Ser-1972- 
Arg,  5’-GlTCAACGAAAAA~GGCG~CTCGCATCITCCAGTCCT-3’. 
The  mutant  DNA  was  inserted  back  into  the  full-length  TORl  gene  by 
subcloning  the  Ncol-Kpnl  mutant  fragment  into  the  HA-tagged  TORl 
construct.  To  introduce  kinase  inactivation  mutations  into  TORl,  the 
Kpnl-Sall  fragment  of  TORl  was  subcloned  into  pBluescript  KS(+). 
In vitro  mutagenesis  was  carried  out  as  above  with  the  following  prim- 
ers:  Arg-2276+Pro,  S’CTGGGACTAGGTGATC~CCATCCAAGCAA- 
CCTG-3’;  Asp2294+Glu,  5%lTATCCACATTGA&lXGGCGAlTG- 
lllTGA-3’.  To  reconstruct  the  full-length  Arg-2276  and  the  Asp-2294 
mutant  TORl  gene,  the  Kpnl-Sall  DNA  fragments  from  the  TOR7  mu- 
tant  mutagenesis  constructs  were  excised,  purified,  and  subcloned 
back  into  the  HA-tagged  wild-type  or  mutant  TOR7.  All mutations  were 
confirmed  by  DNA  sequencing. 
To  construct  TOR2-TORl  mutants,  the  BamHI-Pstl  fragment  of 
wild-type  and  mutant  TORl,  which  contains  codons  1661-2470  and 
the  3’-noncoding  sequences  of  TORl,  were  excised  from  the  above 
TORl  expression  construct  and  fused  with  a  TOR2  genomic  DNA  con- 
taining  the  upstream  promoter  region  and  codons  1-1666  in  pRS315. 
The  TORl-45  wild-type  and  mutant  DNA  fragments  were  subcloned 
into  the  BamHI-EcoRI  sites  of  pYES  (2  PM,  GALl)  (Invitrogen). 
Testing  Growth  PropertIes  of  Yeast  Strains 
To  test  the  growth  of  yeast  strains  on  plates,  freshly  grown  yeast  colo- 
nies  were  streaked  onto  selection  plates  containing  either  glucose 
or  galactose  in  the  presence  or  absence  of  100  nM  rapamycin  and 
incubated  for  3-4  days  at  30%.  To  test  the  growth  of  yeast  strains in liquid  culture,  yeast  cells  were  first  grown  overnight  in glucose  selec- 
tion  medium,  diluted  into  YP-sucrose  medium  at  OD,  =  0.25,  and 
incubated  for  2  hr  at  30%.  Cells  were  pelleted  and  resuspended  into 
YP-galactose  medium.  Cells  were  incubated  at  30%  with  shaking. 
Aliquots  of  1 ml  culture  were  drawn  at  different  times  for  OD  measure- 
ments  at  800  nM. 
TORI  and  TOR2  Dlaruptlona 
The  TORI  disruption  vector  was  constructed  by  inserting  the  Bglll- 
Sglll  fragment  from  YEpl3  containing  the  LEM  selection  marker  gene 
into  the  BamHl  site  of  TORI  in  pBluescript  TORlSK.  The  gene  disrup- 
tion  construct  was  linearized  and  transform  into  haploid  YKFOO7 
strain  selecting  for  leucine  (tor7::LEf.Q)  prototrophy.  The  disruption  of 
the  TORI  locus  was  confirmed  by  PCR  analyses  of  genomic  DNA 
prepared  from  these  LEU2’clones  with  one  TORI  primer  (5’-AAC  GCC 
AGA  GAT  lTG  CTT  GTGS’)  and  with  one  LEU2  primer  (5’-GAT  ClT 
Cl-T  AGG  GGC  AGA  CAT-3’). 
The  Sphl-Smal  fragment  of  TOR2  was  subcloned  into  pTZl8  (Sio- 
Rad)  vector  to  give  pTz-TOR2SS.  The  TOR2  disruption  vector  was 
constructed  by  inserting  eitherthe  same  Bglll-Bglll  fragment  of  aLEU2 
marker  gene  as  above,  or  a  Bglll-BamHI  fragment  that  contains  a 
HEG-URA-HISG  marker  gene  cassette  from  PNKY51  into  the  SamHl 
site  of  TOR2.  The  LEU2  disruption  plasmid  was  linearized  and  trans- 
formed  into  diploid  wild-type  YFKoO7  (MATa/a  TORI/TOR1)  or  homo- 
zygous  TORI  (Ser-1972*Arg)  mutant  (MATala  TORI  [Ser-1972+Argy 
TOR7  [Ser-1972+Arg])  selecting  for  leucine  or  uracil  prototrophies. 
The  HI.%&URA-HISG  disruption  construct  was  linearized  and  intro- 
duced  into  a  diploid  strain  NKY260.  The  heterozygous  disruption  of 
the  7OR2locus  wasconfirmed  by  PCRanalysesofthe  TOR2disruption 
with  one  TOR2  primer  @‘-GAG  GTA  GAA  lTC  lTA  GAA  GAGS’),  one 
EU2  primer  (5%AT  CIT  ClT  AGG  GGC  AGA  CATJ’),  or  one  HlSG 
primer  (6’-TAA  GCG  GOT  GGT  GTC  TAA  CAT-3’).  Diploid  strains  het- 
erozygous  for  TOR2  disruption  were  sporulated  by  patching  yeast  cells 
onto  sporulation  medium  and  incubating  at  room  temperature  and 
were  dissected  on  YPD.  After  viable  spores  formed  colonies  on  YPD 
plates,  replica  plates  were  made  with  synthetic  medium  for  testing 
cosegregation  of  the  selective  markers. 
Complementation  of  the  Temperature  Sensitivity 
of  a  forf  Mutant  Strain 
A  Xhol-SamHI  fragment  (nucleotides  1289-2473)  and  Sacll-SamHI 
fragment  (nucleotides  39016348)  of  TORI  were  cloned  in  a  three 
part  ligation  into  pRS304  (Sikorski  and  Hieter,  1989)  to  create  pYDF79. 
pYDF79  was  linearized  with  BamHl  and  transformed  into  YMWl  (M. 
Wahlberg,  University  of  Texas  Southwestern).  A  transformant  was 
picked  for  Southern  blot  analysis  to  confirm  that  it  does  contain  a  tori 
deletion.  This  mutant  grows  about  80%  as  fast  as  the  wild-type  strain 
at  24%  and  30%  but  is  arrested  at  37% 
Acknowledgments 
We  are  grateful  to  Liurhong  Xu  for  discussions  and  reagents,  Eric 
Brown  for  technical  assistance,  Peter  A.  Beal  for  participation  in  the 
TOR  lipid  kinase  assays,  and  Eric  Brown,  Peter  A.  Beal.  Tae-Bum 
Shin,  and  Curtis  Keith  for  sharing  unpublished  information.  Thii  work 
was  supported  by  grants  (CA-39812  to  G.  R.  C.;  GM-38827  to  S.  L. 
S.)  from  the  National  Institutes  of  Health.  X.-F.  Z.  is  supported  by 
the  Cancer  Research  Fund  of  the  Damon  Runyon-Walter  Winchell 
Foundation  Fellowship  DRG-1278.  J.  C.  is  supported  by  a  fellowship 
from  the  Irvington  Institute.  G.  R.  C.  and  S.  L.  S.  are  Investigators  at 
the  Howard  Hughes  Medical  Institute. 
Received  March  17.  1995;  revised  May  19,  1995. 
References 
Suechler,  Y.,  and  Taylor  S.  (1991).  Mutations  in the  autoinhibitor  site 
of  the  regulatory  subunit  of  CAMP-dependent  protein  kinase  I. J.  Biol. 
Chem.  2663491-3497. 
Cafferkey,  R.,  Young,  P.,  McLaughlin,  M.,  Bergsma,  D.,  Koltin,  Y., 
Sathe,  G.,  Faucette,  L.,  Eng,  W.-K.,  Johnson,  R.,  and  Livi,  G.  (1993). 
Dominant  m&sense  mutations  in a  novel  yeast  protein  related  to  mam- 
malian  phosphatidylinositol  Skinase  and  VPS34  abrogate  rapamycin 
cytotoxicity.  Mol.  Cell.  Biil.  73,  8012-8023. 
Carpenter,  C..  and  Cantley,  L.  (1990).  Phosphoinositide  kinases.  Bio- 
chemistry  29,  11149-I  1158. 
Chiu,  M..  Katz,  H.,  and  Berlin,  V.  (1994).  RAFfl,  a  mammalian  homo- 
log  of yeast  TOR,  interacts  with  the  FKBPI  2/rapamycin  complex.  Proc. 
Natl.  Acad.  Sci.  USA  97,  12574-12578. 
Dhand,  R.,  Hara,  K.,  Hiles,  I.,  Bax,  B.,  Gout,  I.,  Panayotou,  G.,  Fry, 
M.,  Yonerawa,  K.,  Kasuga,  M.,  and  Waterfield,  M.  (1994).  PI bkinase, 
structural  and  functional  analysis  of  intersubunit  interactions.  EMBO 
J.  73,  511-521. 
Divecha.  N.,  and  Irvine  R.  (1995).  Phospholipid  signaling.  Cell  80, 
289-278. 
Guthrie,  C.,  and  Fink,  G.  (1991).  Guide  to  yeast  genetics  and  molecular 
biology.  Meth.  Enzymol  794. 
Gyuris.  J..  Golemis,  E.,  Chertkov,  H..  and  Brent,  R.  (1993).  Cdil,  a 
human  Gi  and  S  phase  protein  phosphatase  that  associates  with 
Cdk2.  Cell  75,791-803. 
Harlow,  E.,  and  Lane  D.  (1988).  Antibodies.  (Cold  Spring  Harbor,  New 
York:  Cold  Spring  Harbor  Laboratory  Press). 
Heitman,  J.,  Movva,  N.,  and  Hail,  M.  (1991).  Targets  for  cell  cycle 
arrest  by  the  immunosuppressant  rapamycin  in  yeast.  Science  253, 
805-909. 
Helliwell,  S.,  Wagner,  P.,  Kunz.  J.,  Deuter-Reinhard,  M.,  Henriquez, 
R.,  and  Hall,  M.  (1994).  TORI  and  TOR2  are  structurally  and  function- 
ally  similar  but  not  identical  phosphatidyfinositol  kinase  homologues 
in  yeast.  Mol.  Biol.  Cell  5,  105-118. 
Kunz,  J.,  Henriquez,  R.,  Schneider,  U.,  Deuter-Reinhard,  M.,  Mowa, 
N.,  and  Hall,  M.  (1993).  Target  of  rapamycin  in  yeast,  TOR2,  is  an 
essential  phosphatidylinositol  kinase  homolog  required  for  Gl  pro- 
gression.  Cell  73,  585-598. 
Liu,  J.,  Farmer,  J.,  Lane,  W.,  Friedman,  J.,  Weissman,  I.,  and 
Schreiber,  S.  (1991).  Calcineurin  is  a  common  target  of  cyclophilin- 
cyclosporin  A  and  FKBP-FK508  complexes.  Cell  66,807-815. 
Sabatini,  D.  Erdjument-Sromage,  H.,  Lui.  M.,  Tempst.  P.,  and  Snyder, 
S.  (1994).  RAFTI,  a  mammalian  protein  that  binds  to  FKBPIP  in  a 
rapamycindepedent  fashion  and  is  homologous  to  yeast  TORs.  Cell 
78,  35-43. 
Schena,  M.,  Picard,  D.,  and  Yamamoto,  K.  (1991).  Vectors  for  wnstitu- 
tive  and  inducible  gene  expression  in yeast.  Meth.  Enzymol.  794,389- 
398. 
Schreiber.  S.  L.  (1992).  lmmunophilin-sensitive  phosphatase  action 
in  cell  cycle  regulatory  pathways.  Cell  70.  365-368. 
Schu,  P.,  Takegawa,  K.,  Fry,  M..  Stack,  J..  Waterfield,  M.,  and  Emr, 
S. (1993).  Phosphatiiyfinositol  Skinase  encoded  by  yeast  VfS34  gene 
essential  for  protein  sorting.  Science  260,  88-91. 
Sikorski,  R.,  and  Hieter,  P.,  (1989).  A  system  of  shuttle  vectors  and 
yeast  host  strains  designed  for  efficient  manipulation  of  DNA  in  Sac- 
chafomyces  cerevisiee.  Genetics  722,  19-27. 
Stack,  J.,  and  Emr,  S.  (1994).  Vps34p  required  for  yeast  vacuolar 
protein  sorting  is  a multiple  specificity  kinase  that  exhibits  both  protein 
kinase  and  phosphatidylinositol-specific  kinase  activities.  J.  Siol. 
Chem.  269,31552-31562. 
Stan,  R.,  McLaughlin,  M.,  Cafferkey.  R.,  Johnson,  R.,  Rosenberg,  M., 
and  Livi,  G.  (1994).  Interaction  between  FKBPIP-rapamycin  and  TOR 
involvesawnserved  serine  residue.  J.  Biol.  Chem.  269,32027-32030. 
Brizuela,  L.,  Chrebet,  G.,  Bostian,  K.,  and  Parent,  S.  (1991).  Antifungal 
properties  of  the  immunosuppressant  FK-508:  identification  of  an  FK- 
508-responsive  yeast  gene  distinct  from  FKBl.  Mol.  Cell.  Biol.  77, 
46184828. 
Brown,  E.,  Albers,  M.,  Shin,  T.,  Ichikawa,  K.,  Keith,  C.,  Lane,  W.,  and 
Schreiber,  S.  (1994).  A  mammalian  protein  targeted  by  Gl-arresting 
rapamycin-receptor  complex.  Nature  369,  758-758. 